pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Astellas Pharma Inc

updated 3mo ago

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. .

Website ↗
community read0 votes

🐶 often sniffed alongside

top 5
  • companyAstellas Pharma US Inc8 co-mentions · 2 sources
  • drugLP-3108 co-mentions · 2 sources
  • tagRecall4 co-mentions · 2 sources
  • drug386574 co-mentions · 2 sources
  • drugTACROLIMUS4 co-mentions · 2 sources
pipeline
8
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
1
recalls ytd
0

Pipeline(8)

pipeline depth8 products
Phase 2: 4Marketed: 1Unknown: 3
4Phase 21Marketed3Unknown
Marketed
enfortumab vedotin
Muscle Invasive Bladder Cancer (MIBC)
Nectin-4Tubulin
Phase 2
ASP-2957
X-Linked Myotubular Myopathy (XLMTM or MTM)
Phase 2
ASP-7316
Juvenile Macular Degeneration (Stargardt Disease)
Phase 2
zocaglusagene nuzaparvovec
Pompe Disease
Phase 2
zolbetuximab
Metastatic Adenocarcinoma of The Pancreas
Claudin-18
drug
IZERVAY
drug
PADCEV
drug
XTANDI

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopauserecruitingn=100
  • phase4A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degenerationactive not recruitingn=17
  • phase1A Study of ASP3082 in Adults With Advanced Solid Tumorsrecruitingn=681
  • phase2A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Strokerecruitingn=84
  • phase1A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumorsrecruitingn=364
  • phase3A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutationactive not recruitingn=276
  • phase3A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopausecompletedn=277
  • —Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritisrecruitingn=3,000
🐶 Hiring Signal
No open roles indexed yet — view Astellas Pharma Inc jobs →

News

  • nChroma halves workforce, BioXcel lets execs go
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 1h ago
  • Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
    Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.
    biopharma_dive · 6d ago
  • With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
    Speaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.
    biospace · 15d ago
  • Lilly shuffles business structure; Novartis writes off part of Avidity deal
    Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.
    biopharma_dive · 22d ago
  • Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
    Astellas Pharma could secure the exclusive global rights to Audax Biosciences’ DAX-044, an antibody-cytokine fusion therapy that activates the immune system in the vicinity of the tumor.
    biospace · 22d ago
  • Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
    Astellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.
    fiercebiotech · 22d ago
  • Astellas links up with AI Proteins in $400M computational drug discovery deal
    Japan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially worth $400 million.
    fiercebiotech · 29d ago
  • Exclusive: Astellas partners with Boston ‘miniproteins’ startup
    Chris Bahl believes AI can help make tiny proteins capable of doing things that bigger and more traditional proteins like antibodies struggle to do. And now the Japanese drugmaker Astellas is buyin…
    endpoints · 1mo ago
  • J&J earnings set ‘negative tone’; Shkreli vs. the FTC
    A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.
    biopharma_dive · 1mo ago
  • From Scientific Hypothesis to Clinical Practice: The Next Chapter for CLDN18.2
    Astellas reflects on a decade of progress in CLDN18.2 and the opportunities ahead in patient identification, testing and innovation
    fiercebiotech · 1mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Oncology2Ophthalmology1
mentioned in
10news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?